Shares of Biogen Inc BIIB were trading up almost 1.2 percent on Thursday afternoon shortly before the closing bell. The movement apparently comes on the back of updated and embargoed aducanumab titration data leaked from the 9th Clinical Trials on Alzheimer's Disease (CTAD) congress.
Unable to resist the temptation, famed analyst Adam Feuerstein tweeted the aducanumab data, which had already been leaked, ahead of the official presentation, scheduled for Friday.
As per the phase I PRIME study, patients treated with a titrated dose of aducanumab showed reduced ARIA rates, or brain bloating, while maintaining cognitive improvements.
Follow the conversation as it unfolds here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
